HMGN1 and neoplasm: Collectively, these results suggested that the HMGN1/αCD4 treatment reduces the level of co-inhibitory molecules in these exhausted CD8+ T cells, increases their effector functions, and decreases the proportion of exhausted CD8+ T cells in the tumor.